← Cytek Biosciences, Inc.
| Annual Trend | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $92.8m |
$128.0m
+37.82%
|
$164.0m
+28.20%
|
$193.0m
+17.67%
|
$200.5m
+3.85%
|
$201.5m
+0.52%
|
$206.7m
+2.59%
|
|
| Cost of Revenue | $41.1m |
$48.8m
+18.67%
|
$63.1m
+29.21%
|
$83.6m
+32.55%
|
$89.3m
+6.89%
|
$97.0m
+8.60%
|
$96.7m
-0.36%
|
|
| Gross Profit | $51.7m |
$79.1m
+53.05%
|
$101.0m
+27.58%
|
$109.4m
+8.37%
|
$111.1m
+1.54%
|
$104.5m
-5.98%
|
$110.0m
+5.33%
|
|
| Research and Development Expense | $13.7m | $24.4m | $34.9m | $44.2m | $39.4m | $36.5m | $37.3m | |
| Marketing and Advertising Expense | $1.0m | $1.8m | $2.5m | $3.4m | $3.8m | $4.2m | — | |
| Selling and Marketing Expense | $15.0m | $24.7m | $33.2m | $49.1m | $49.1m | $49.4m | $117.4m | |
| General and Administrative Expense | $9.4m | $20.8m | $34.7m | $44.0m | $43.1m | $58.9m | $67.8m | |
| Amortization of Intangible Assets | $71k | $334k | $835k | $3.3m | $3.7m | $3.7m | — | |
| Operating Expenses | $38.1m | $70.0m | $102.8m | $137.3m | $131.6m | $144.8m | $154.7m | |
| Operating Income (Loss) | $13.7m |
$9.2m
-32.96%
|
($1.8m)
-119.70%
|
($27.8m)
-1443.51%
|
($20.5m)
+26.30%
|
($40.4m)
-96.77%
|
($44.6m)
-10.56%
|
|
| Interest Expense | $333k | $1.7m | $2.6m | $2.1m | — | — | $312k | |
| Investment Income, Interest | $110k | $49k | $4.6m | $6.4m | $5.1m | $2.2m | — | |
| Gain (Loss) Related to Litigation Settlement | — | — | — | — | — | ($1.0m) | — | |
| Other Nonoperating Income (Expense) | $994k | ($1.5m) | $1.0m | $7.8m | $4.5m | $8.8m | — | |
| Interest Expense (non-operating) | — | — | — | — | ($5.2m) | $474k | $312k | |
| Nonoperating Income (Expense) | $771k | ($3.2m) | $3.1m | $12.1m | $14.8m | $10.5m | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | $14.1m | ($1.9m) | ($1.3m) | ($16.9m) | ($12.8m) | ($44.5m) | ($40.8m) | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | $14.4m | $5.9m | $1.3m | ($15.7m) | ($5.7m) | ($29.8m) | ($40.8m) | |
| Current Income Tax Expense (Benefit) | $2.4m | $4.7m | $10.1m | $6.5m | $3.2m | $3.1m | $39.8m | |
| Income Tax Expense (Benefit) | ($5.0m) | $2.9m | ($1.2m) | ($3.6m) | $320k | $36.7m | $39.8m | |
| Net Income (Loss) Attributable to Parent | $19.4m |
$3.0m
-84.41%
|
$2.5m
-17.94%
|
($12.1m)
-589.05%
|
($6.0m)
+50.44%
|
($66.5m)
-1005.30%
|
($80.6m)
-21.10%
|
|
| Net Income (Loss) Available to Common Stockholders, Basic | $3.2m |
$0
-100.00%
|
$2.6m |
($12.1m)
-571.58%
|
($6.0m)
+50.44%
|
($66.5m)
-1005.30%
|
($80.6m)
-21.10%
|
|
| Net Income (Loss) Attributable to Noncontrolling Interest | — | $26k | $92k | $0 | $0 | $0 | ($80.6m) | |
| Undistributed Earnings (Loss) Allocated to Participating Securities, Basic | ($16.2m) | ($3.0m) | $0 | $0 | — | — | — | |
| Earnings Per Share, Basic | $0.11 | $0.00 | $0.02 | ($0.09) | ($0) | ($1) | ($0.63) | |
| Earnings Per Share, Diluted | $0.10 | $0.00 | $0.02 | ($0.09) | ($0) | ($1) | ($0.63) | |
| Income (Loss) from Continuing Operations, Per Basic Share | $0 | $0 | $0 | ($0) | ($0) | ($1) | — | |
| Income (Loss) from Continuing Operations, Per Diluted Share | $0 | $0 | $0 | ($0) | ($0) | ($1) | — | |
| Weighted Average Number of Shares Outstanding, Basic | 29.1m | 76.7m | 134.5m | 135.3m | 130.6m | 127.7m | 128.5m | |
| Weighted Average Number of Shares Outstanding, Diluted | 32.6m | 81.5m | 138.6m | 135.3m | 130.6m | 127.7m | 128.5m | |
| Additional Financial Items | ||||||||
| Business Combination, Acquisition Related Costs | — | — | — | $1.5m | — | — | — |